Offering biomedical innovators the experience, expertise, and funding required for success.
Through the RCT Ventures program, venture capital is provided to start-up or early-stage companies with technologies that have the potential to become significant biomedical products with a definite competitive edge. Learn more ›
RCT develops and invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics. Many of these life science tools are available from RCT through affordable nonexclusive licensing. Learn more ›
WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it acquired of Distributed Bio, Inc. on December 31, 2020. The acquisition marks the culmination of an exclusive partnership between these companies that was initiated in October 2018. … Learn more